



28<sup>th</sup> September 2010

**Micafungin (Mycamine ®) for the treatment of invasive candidiasis.**

The New Therapies Subgroup discussed the above drug at a meeting on the 21<sup>st</sup> October 2008 and September 28<sup>th</sup> 2010. The recommendation of this subgroup is as follows:\*

The New Therapies Subgroup of the GMMMG considered the use of Micafungin (Mycamine ®▼) for the treatment of invasive candidiasis.

**The group recommends that Micafungin (Mycamine ®▼) may be considered as a treatment option for patients that have failed standard antifungal therapy. Micafungin should be used in line with treatment protocols available from University Hospital of South Manchester NHS Foundation Trust.**

The group recommends that micafungin should only be initiated by a physician experienced in the management of fungal infections as per its summary of product characteristics (SPC)

Animal studies with Micafungin showed a potential risk for the development of liver tumours in female rats at high sustained doses. Whilst this hasn't been seen in human studies this risk cannot be ruled out and therefore liver function tests should be monitored carefully during treatment with Micafungin, as with all antifungal agents.

Review date: September 2012

\* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.